on July 14, 2005
Published online before print July 14, 2005, doi: 10.1161/01.ATV.0000177813.99577.6b
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 19, 2003
Accepted on July 1, 2005
Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects
Anna C. Calkin *;
From JDRF Danielle Alberti Memorial Centre for Diabetes Complications (A.C.C., J.M.F., C.M.S., M.L., M.E.C., K.A.J.-D., T.J.A.), Vascular Division, Wynn Domain, Baker Heart Research Institute, and the Department of Medicine (A.C.C.), Monash University, Melbourne, Australia.
* To whom correspondence should be addressed. E-mail: anna.calkin{at}baker.edu.au.
Objectives--Recent studies have demonstrated a role for thiazolidinediones in attenuating atherosclerosis. However, these studies were performed in insulin-resistant animal models in association with reductions in insulin and glucose levels. To assess the vascular effects of thiazolidinediones, independent of their metabolic effects, we observed the effect of rosiglitazone on diabetes-associated atherosclerosis in a model of insulin insufficiency.
Methods and Results--Control and diabetic apolipoprotein E-deficient mice received rosiglitazone or placebo. Diabetic mice demonstrated a 3-fold increase in plaque area, which was attenuated by rosiglitazone. There was no significant difference in glucose, insulin, or cholesterol levels between treated and untreated diabetic animals. Rosiglitazone attenuated the increase in superoxide production observed in diabetic mice. A 4-fold increase in the reverse cholesterol transport marker ABCA1 was observed in treated diabetic mice. Rosiglitazone reduced angiotensin II receptor gene expression in control and diabetic mice, and macrophage accumulation was increased in diabetic mice compared with controls and was attenuated by rosiglitazone.
Conclusions--These findings suggest peroxisome proliferator-activated receptor-
ligands such as rosiglitazone confer vascular protection independent of their effects on metabolic control. These antiatherosclerotic effects may have important clinical ramifications not only in insulin resistance/type 2 diabetes and also in type 1 diabetes.
Key words: ABCA1 • atherosclerosis • diabetes • macrophages • oxidative stress
This article has been cited by other articles:
 |
|
 |
|
  A. Soro-Paavonen, A. M.D. Watson, J. Li, K. Paavonen, A. Koitka, A. C. Calkin, D. Barit, M. T. Coughlan, B. G. Drew, G. I. Lancaster, et al. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes Diabetes, September 1, 2008; 57(9): 2461 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Demozay, J.-C. Mas, S. Rocchi, and E. Van Obberghen FALDH Reverses the Deleterious Action of Oxidative Stress Induced by Lipid Peroxidation Product 4-Hydroxynonenal on Insulin Signaling in 3T3-L1 Adipocytes Diabetes, May 1, 2008; 57(5): 1216 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Duan, M. G. Usher, and R. M. Mortensen Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature Circ. Res., February 15, 2008; 102(3): 283 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al. Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2627 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Askari, J. E. Kanter, A. M. Sherrid, D. L. Golej, A. T. Bender, J. Liu, W. A. Hsueh, J. A. Beavo, R. A. Coleman, and K. E. Bornfeldt Rosiglitazone Inhibits Acyl-CoA Synthetase Activity and Fatty Acid Partitioning to Diacylglycerol and Triacylglycerol via a Peroxisome Proliferator-Activated Receptor-{gamma}-Independent Mechanism in Human Arterial Smooth Muscle Cells and Macrophages Diabetes, April 1, 2007; 56(4): 1143 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas PPAR-{alpha} and -{gamma} agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2399 - 2405. [Abstract] [Full Text] [PDF]
|
|